Complete Blood Count Analysis in the Early Detection of Blood Cancers
Author: Pallavi Bollineni
Blood cancer, which is also referred to as hematologic malignancy, disrupts the production and function of blood cells. This originates primarily in the bone marrow. The three main types are leukemia, lymphoma, and myeloma, each of which interferes with the body’s ability to produce healthy blood cells endogenously. DNA mutations in blood cells cause blood cancer and are often prompted by external factors.
Blood cells are normally produced in the bone marrow, but when cancer cells start to seep through, the mutation causes the bone marrow to create abnormally large amounts of white blood cells that are not functional. Over time, these defective cells become abundant and gradually crowd out healthy blood. Early detection of blood cancer is critical, as it significantly improves treatment outcomes and survival rates. One of the most valuable tools for early detection is the Complete Blood Count test (CBC), which is among the most common and impactful laboratory tests in medicine.
How CBC Works
The complete blood count analysis test is easily one of the most accessible and most administered. The test is performed through a simple blood draw, which is then analyzed by an automated machine that counts and evaluates the cells in the sample. CBC measures your three primary blood cells: white, red, and platelets. RBCs carry oxygen and carbon dioxide away from your body, while WBCs fight infection and disease, and platelets control your bleeding by forming clots. The CBC also includes a differential count, which breaks down and measures the percentage and absolute count of each type of white blood cell in your blood, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. If an abnormal result is flagged, a peripheral blood smear may be performed. This is when the blood sample is placed on a slide and examined under a microscope.
CBC Abnormalities & Blood Cancer
Abnormal CBC results can be a very prevalent indicator of blood cancer. Both abnormally high and low white blood cell counts can trigger the identification of hematologic malignancies like leukemia, lymphoma, and myeloma. Specifically, leukopenia, which is the medical term for a WBC count below 4,000 cells/µL (cells per microliter), leaves patients vulnerable to infection because WBCs fight off sickness and are now scant. A low neutrophil count, which is known as neutropenia, has been linked to acute leukemia and myelodysplasia (Myelodysplastic Syndrome is a group of rare blood cancers where the bone marrow produces immature blood cells that die shortly after entering the bloodstream). Neutrophils are the most plentiful type of white blood cells and serve as the immune system’s primary defense. Abnormal hemoglobin levels can also indicate early stages of anemia, which is a common symptom of blood cancer. Low platelet counts, known as thrombocytopenia, are also frequently associated with hematologic malignancies. When the CBC reveals abnormal results, flow cytometry is conducted to analyze and classify the cells and guide the diagnostic process. Flow cytometry is a laboratory technique used to investigate the physical characteristics of cells, and they flow in a fluid stream through a laser beam. It is primarily used to sort and profile specific cell types in blood, bone marrow, or tissue suspensions.
Limitations
While CBC is an extremely valuable screening tool, it has several limitations in the diagnosis of hematologic malignancies. One of the main challenges is that different types of blood cancer share very similar symptoms, making it difficult to reach a definitive conclusion through CBC results alone because it can’t differentiate between the types of leukemia, such as acute versus chronic or myeloid versus lymphoid. Because of this, tests like bone marrow examination, immunophenotyping, and cytogenetic testing are required to reach a full diagnosis. Physicians tend to focus only on values that are very evidently outside the reference range, which can cause critical diagnostic information to be overlooked. Even experienced hematologists can fail to see subtle trends and patterns within CBC data.
The Future of CBC
Despite these limitations, the CBC’s speed, accessibility, and cost-effectiveness make it essential. As research continues to advance, the integration of artificial intelligence and machine learning with CBC data holds promise for improving early detection and differentiation of blood cancer types. CBC-focused AI models have shown high accuracy in distinguishing between leukemia types. This is especially valuable in clinical settings that don’t specialize in hematology, as it assists in early screenings and referral of patients who require hematological care.
Works Cited
Saha, Sayan, et al. A Comprehensive Review on Unravelling the Complexity of Blood Cancer . 15 Mar. 2024,
“Blood Tests.” Cancer.org, 2020, www.cancer.org/cancer/diagnosis-staging/tests/blood-tests.html.
Osa-Andrews , Bremansu , et al. “An Introduction to the Complete Blood Count for Clinical Chemists: White Blood Cells.” Oxford Academic, Mar. 2025, academic.oup.com/jalm/article/10/2/459/7985330?guestAccessKey=.
Haider, Rana Zeeshan, et al. “Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias.” Diagnostics, vol. 12, no. 1, 7 Jan. 2022, p. 138, https://doi.org/10.3390/diagnostics12010138.
Comments